Skip to main content Skip to main navigation menu Skip to site footer

Prognostic significance of double expressor lymphoma subtype in patient with diffuse large B-cell lymphoma


Background: DLBCL is the most common type of non-Hodgkin lymphoma in Asia and Indonesia. DLBCL, based on cell of origin is divided into germinal center B-cell-like (GCB) and non-GCB subtypes. 20% of patients have a molecular profile double expressor lymphoma (DEL), which has a worse prognosis. The study aims to determine the relationship between DEL subtypes and cell of origin subtypes with clinical stage and 3-year overall survival of double large B-cell lymphoma (DLBCL) patients in Kariadi General Hospital Semarang.

Methods: This study sample was 36 DLBCL patients in Kariadi General Hospital from January to September 2017. The data collection including age of diagnosis, location, stage, cell of origin subtype, DEL subtype and 3-year overall survival. Data analysis using chi-square test and Kaplan Meier curve.

Results: DLBCL DEL subtype patients were significantly associated with advanced-stage (p: 0.028). DLBCL non-GCB subtype and DEL subtype patients had a 3-year overall survival that was significantly worse than GCB subtype and non-DEL subtypes (p: 0.026 and p: 0.006, respectively), with a 3-year survival rate of non-GCB subtypes was 38.9% and DEL subtypes were 33.3%. DLBCL patients with advanced stages also have a 3-year overall survival significantly worse than the early stage (p: 0.000), with a 3-year survival rate of 14.3%.

Conclusion: DLBCL non-GCB subtype patients, DEL subtypes and advanced stages have a lower 3-year overall survival rate and thus have a worse prognosis


  1. Rosai J. Lymph Nodes. In: Rosai and Ackerman's Surgical Pathology. 10 Ed. (Rosai J, ed.). Philadelpia: Elsevier Inc; 2011.
  2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2017;127(20):2375-2391. doi:10.1182/blood-2016-01-643569.The.
  3. Habara T, Sato Y, Takata K, et al. Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor localized nodal DLBCL. J Clin Exp Hematop. 2012;52:91-99.
  4. Syahrin RA. Difference of Caspase-3 Immunoexpression between Diffuse Large B-Cell Lymphoma Subtypes Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like. Indonesian Journal of Pathology. 2013;27(1):1-8.
  5. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flower CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14(6):460-467. doi:10.1016/j.clml.2014.05.002.
  6. Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015;(January):1069-1080. doi:10.1093/annonc/mdv019.
  7. Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed / refractory diffuse large B-cell lymphoma : a comprehensive review. Mol Cancer. 2015:1-62. doi:10.1186/s12943-015-0474-2.
  8. Green TM, Young KH, Visco C, et al. Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide , Doxorubicin , Vincristine , and Prednisone. J Clin Oncol. 2012;30(28):3460-3467. doi:10.1200/JCO.2011.41.4342.
  9. Horn H, Ziepert M, Becher C, et al. Lymphoid Neoplasia MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253-2264. doi:10.1182/blood-2012-06-435842.H.H.
  10. Yan L, Liu Y, Luo D, et al. MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma , Not Otherwise Specified. PLoS Med. 2014;9(8):1-16. doi:10.1371/journal.pone.0104068.
  11. Wahyudianingsih R, Hernowo BS, Hassan AH, Dewayani BM. Relationship between Bcl-2 and Caspase-3 Immunoexpression and CHOP Chemotherapy Response in Non-Hodgkin's Malignant Lymphoma CD20 Positive B-Cell Type. Indonesian Journal of Pathology. 2013;22(2):17-24.
  12. Bogusz AM, Kovach AE, Le LP. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence. PLoS One. 2017;12(2):1-14. doi:10.1371/journal.pone.0172364.
  13. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2018;123(6):837-843. doi:10.1182/blood-2013-09-524108.The.
  14. Li S, Young KH, Edeiros LJEM. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87. doi:10.1016/j.pathol.2017.09.006.
  15. Ventre MB, Ferreri AJM, Gospodarowicz M, et al. Clinical Features , Management , and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). Oncologist. 2014;19:291-298.
  16. Gogia A, Das CK, Kumar L, et al. Leukemia, Lymphoma & Plasma cell disorder Diffuse large B ‑ cell lymphoma : An institutional analysis. South Asian J Cancer. 2018;7:200-202. doi:10.4103/sajc.sajc.
  17. Abdelhamid T, Samra M, Ramadan H. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma : A retrospective study. J Egypt Natl Canc Inst. 2011;23(1):17-24. doi:10.1016/j.jnci.2011.07.003.
  18. Salles G, Jong D De, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma : a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2018;117(26):7070-7079. doi:10.1182/blood-2011-04-345256.The.
  19. Yoo C, Kim S, Sohn BS, et al. Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma. Korean J Intern Med. 2010;25(3):301-308. doi:10.3904/kjim.2010.25.3.301.
  20. Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H. MYC translocation and â„ or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. 2016;107(6). doi:10.1111/cas.12942.
  21. Hwang HS, Park C, Yoon DH, Suh C, Huh J. High Concordance of Gene Expression Profiling – correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma. Am J Surg Pathol. 2014;38(8):1046-1057.
  22. Li T, Medeiros LJ, Lin P, et al. Immunohistochemical Profile and Fluorescence In Situ Hybridization Analysis of Diffuse Large B-Cell Lymphoma. Arch Pathol Lab Med. 2010;134:759-765.
  23. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. doi: 10.1038/35000501.
  24. Benesova K, Forsterova K, Votavova H, et al. The Hans algorithm failed to predict outcomes in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma. 2013;60(1):68-73. doi:10.4149/neo.
  25. Bellas C, García D, Vicente Y, Kilany L, Abraira V, Navarro B, Provencio M, Martín P. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS One. 2014;9(6):e98169. doi: 10.1371/journal.pone.0098169.
  26. Hu S, Xu-monette ZY, Tzankov A, et al. MYC / BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures : a report from The International DLBCL Rituximab-CHOP Consortium Progr. Blood. 2018;121(20):4021-4032. doi:10.1182/blood-2012-10-460063.
  27. Pedersen MØ, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma – a single centre' s experience. Eur J Haematol. 2012;89(1):13-15. doi:10.1111/j.1600-0609.2012.01787.x.
  28. Li S, Seegmiller AC, Lin P. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC / BCL2 double-hit lymphomas. Mod Pathol. 2014;28(2):208-217. doi:10.1038/modpathol.2014.95.
  29. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47. doi: 10.1056/NEJMoa012914.
  30. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. PNAS. 2012;109(10):3879-3884. doi:10.1073/pnas.1121343109.
  31. Rossi D, Ciardullo C, Gaidano G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next-generation sequencing studies. Semin Cancer Biol. 2013;23(6):422-30. doi: 10.1016/j.semcancer.2013.04.002.

How to Cite

Istiadi, H., Sadhana, U., Puspasari, D., Miranti, I. P., Karlowee, V., Listiana, D. E., & Prasetyo, A. (2021). Prognostic significance of double expressor lymphoma subtype in patient with diffuse large B-cell lymphoma. Bali Medical Journal, 10(1), 366–372.




Search Panel